FDA breaks with expert advisers in rejecting Titan addiction med

In the end, a vote by an outside panel of FDA experts favoring approval of Titan Pharmaceuticals' Probuphine didn't influence the outcome at all. Agency staffers stuck with the opinions outlined in a harsh internal review and rejected the opioid addiction drug. Report